3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
6
Thoracic
3
Gastrointestinal
2
CNS
2
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Brain Neoplasms
2
Meningeal Neoplasms
1
Breast Neoplasms
1
Interventions
Temozolomide
258
Radiotherapy
147
Bevacizumab
142
Etoposide
68
Cyclophosphamide
68
Carboplatin
66
Magnetic Resonance Spectroscopy
58
Irinotecan
53
Cisplatin
52
Vincristine
45
Filgrastim
43
pembrolizumab
40
Radiosurgery
36
Nivolumab
36
Radiation
34
Topotecan
31
Doxorubicin
30
Specimen Handling
29
sargramostim
28
Lomustine
27
Erlotinib Hydrochloride
27
Peripheral Blood Stem Cell Transplantation
25
Carmustine
25
Thiotepa
24
Everolimus
23
Chemotherapy, Adjuvant
23
Surgical Procedures, Operative
22
Isotretinoin
22
Ipilimumab
22
Melphalan
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
patritumab deruxtecan
×
CNS
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn